On March 25, 2026, MeiraGTx Holdings plc (the "Company") entered into Amendment No. 4 to its Amended and Restated Notes Purchase Agreement and Amendment No. 1 to Warrant Certificates with its wholly-owned subsidiaries and Perceptive Credit Holdings III, LP. The amendments extend the maturity date of the notes from August 2, 2026, to May 2, 2027, and require the Company to redeem $25 million of the outstanding principal amount of the notes by June 30, 2026. Additionally, the exercise price of the warrants has been reduced to $8.00 per share from previous prices of $15.00 and $20.00. This strategic move is expected to enhance the Company's liquidity position and provide a clearer path for future financing. Furthermore, the Company announced its financial results for the year ended December 31, 2025, reporting a net loss of $114.2 million, a decrease from the previous year's loss of $147.8 million. The Company also highlighted its ongoing collaborations and the potential for significant cash inflows from milestone payments related to its partnerships with Eli Lilly and Hologen Limited. The amendments and financial results indicate a proactive approach by MeiraGTx to strengthen its financial standing and operational execution as it navigates the complexities of the biotech landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.